- Home
- NTRB vs PSNL Comparison
NTRB vs PSNL Comparison
Compare NTRB & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | PSNL |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 872.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NTRB | PSNL |
|---|---|---|
| Price | $4.52 | $8.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $13.00 | $10.71 |
| AVG Volume (30 Days) | 22.3K | ★ 1.7M |
| Earning Date | 12-11-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,278,321.00 | ★ $69,103,000.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.72 | $2.83 |
| 52 Week High | $11.78 | $11.40 |
Technical Indicators
Market Signals| Indicator | NTRB | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 48.45 |
| Support Level | $4.35 | $7.68 |
| Resistance Level | $4.77 | $9.85 |
| Average True Range (ATR) | 0.42 | 0.57 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 7.25 | 36.88 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.